Glaxo’s cervical cancer vaccine faces U.S. battle

TRENTON - New studies show that GlaxoSmithKline PLC's vaccine Cervarix blocks the virus that causes cervical cancer, but if it wins approval for U.S. sales, it will face an uphill battle against Gardasil, which has owned the market here for three years.

Copyright PHILY -
Contact Us